BG Lab shared a post about an article co-authored by Mirat Shah, et al., on X:
“Have you noticed this new correspondence in Journal of Clinical Oncology from the FDA about PARP inhibitors in ovarian cancer? This is a great read, and we Oncology BG Lab completely agree with the FDA!.
We have been advocating for this for a long time. Highly recommended reading.
If you want to read some more about PARP inhibitors in ovarian cancer, please read these from Bishal Gyawali
and this.”
Title: Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Authors: Mirat Shah, Mallorie H. Fiero, Joyce Cheng, Ting-Yu Chen, Gwynn Ison, Richard Pazdur, and Laleh Amiri-Kordestani.
Read the full article on Journal of Clinical Oncology.
You Can Also Read: Ovarian Cancer: Symptoms, Causes, Stages, Diagnosis and Treatment
